The settlement agreement followed the recent Markman Hearing ruling by a Federal Court Judge in the Southern District of New York relating to claim terms in eight patents asserted against Sigma. Terms of the settlement are confidential.
“Enzo is pleased to have settled with Sigma-Aldrich on favorable terms. Sigma is the first defendant to settle in the various actions brought by Enzo. Additional defendants in the various actions include Affymetrix Inc., Roche Diagnostics, Amersham Biosciences, Inc., Perkin Elmer, Inc., Orchid Biosciences, Inc. and Molecular Probes, Inc. We continue to aggressively pursue our claims with respect to the remaining defendants,” the Company said.
Enzo is represented in the litigations by Greenberg Traurig, LLP.
About Enzo
Enzo Biochem and its subsidiaries (the Company) are engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis, uveitis, Crohn's disease, and for NASH and its associated metabolic syndrome. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
###
Contacts;
For: Enzo Biochem, Inc.
Steve Anreder, 212-532-3232 Or Ed Lewis, CEOcast, Inc., 212-732-4300